New Advances in Tumor Metastasis Angiogenesis-Dependent Processes
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Pathophysiology".
Deadline for manuscript submissions: closed (15 September 2023) | Viewed by 4201
Special Issue Editors
Interests: pathological and physiological angiogenesis; anti-angiogenic therapy; anti-metastatic therapy
Interests: breast cancer metastasis; biomarkers; therapy; translational studies
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
In 2022, the World Health Organization estimates that cancer is the leading cause of death worldwide. The spreading of tumor cells from the primary tumor to surrounding tissues and distant organs, also called metastasis, constitutes the main cause of cancer-associated morbidity and mortality worldwide. It occurs in a wide range of solid tumors including breast, colorectal, liver, skin cancers, and others. It has been estimated that 90% of cancer deaths are due to metastasis. Tumor angiogenesis is a fundamental biological event involved in tumor development and progression. It is essential for the dissemination of cancer cells from the primary tumor through the cooperation of several other microenvironment cell types (i.e., pericytes, fibroblasts, macrophages…) and cancer cells themselves. In addition, angiogenesis is also involved in the development of metastasis into distant organs through promoting or blocking mechanisms (i.e., metastasis growth vs. angiogenic dormancy). The cellular and molecular mechanisms behind the angiogenic role in metastatic spreading are still under investigation. Defining them is crucial to highlight novel potential therapeutic opportunities and combinations and overcome therapeutic resistance altogether to increase patient survival.
This Special Issue will cover the following topics:
- Angiogenic cellular and molecular mechanisms regulating metastatic spreading and metastasis growth.
- Anti-angiogenic therapies for metastatic spreading and metastasis growth targeting.
Review, research articles, and clinical evaluations are welcome.
Dr. Jimmy Stalin
Prof. Dr. Curzio R. Rüegg
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- angiogenic dormancy
- anti-angiogenic therapy
- anti-metastatic therapy
- tumor angiogenesis
- tumor metastasis
- endothelial cells
- pericytes
- tumor microenvironment
